William Kochen

Dr. William Kochen

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
KCKristen M. Craven
Kristen M. Craven
WKWilliam Kochen
William Kochen
CHCarlos M. Hernandez
Carlos M. Hernandez
JFJANE M FLINN
JANE M FLINN
Hyperphosphorylated tau protein is a key pathology in Alzheimer’s disease (AD), frontotemporal dementia, chronic traumatic encephalopathy, and Parkinson’s disease. The essential trace element zinc exacerbates tauopathy in vitro as well as in a Drosop

7 May 2019 in Cortex
Verified
Journal Article
Closed access
FBFarah Bader
Farah Bader
WKWilliam Kochen
William Kochen
MKMarilyn Kraus
Marilyn Kraus
MWMartin Wiener
Martin Wiener

Verified
Journal Article
Open access
PDF file
LTLUIS MANUEL SALGUEIRO TOSTA
LUIS MANUEL SALGUEIRO TOSTA
AJArumugam Radhakrishnan Jayakumar
Arumugam Radhakrishnan Jayakumar
WKWilliam Kochen
William Kochen
RCRenzhi Cai
Renzhi Cai
WSWei Sha
Wei Sha
NKNancy Klimas
Nancy Klimas
Gulf War illness (GWI) is a multi-symptom disorder affecting veterans of the Persian Gulf operations. Persistent neuroendocrine dysregulation contributes to impairing cognitive capacity and generates anxiety-like behavior. Effective treatments for this illness are challenging due to compromised metabolism, increased oxidative stress and neuroinflammation, perpetuated by chronic stress and hypothalamic–pituitary–adrenal (HPA) axis dysfunction. This neuroinflammation can be alleviated with synthetic antagonistic analogs of the growth hormone-releasing hormone (GHRH) through modulation of the HPA axis. We evaluated the efficacy of the GHRH antagonist analog, MIA-690, against cognitive impairment and anxiety-like behavior in GWI. Mice exposed to an experimental GWI model involving corticosterone (CORT) and diisopropylfluorophosphate (DFP), followed by CORT and lipopolysaccharide (LPS), received a daily subcutaneous dose of 10 μg of MIA-690 for 10 days. Assessments of spatial memory, recognition capacity, somatic health, anxiety and innate survival were carried out, combining the Morris water maze (MWM), novel object recognition (NORT), grip strength (GST), and open field (OFT) tests. Learning efficiency was selectively enhanced in females using the MWM. There were no significant differences in the recall capacity and performance on the OFT, NOR, and GST tasks. Our findings suggest that the MIA-690 dosage is sufficient to improve learning deficits in experimental GWI exposures.